JPH0747589B2 - 多環式グアニン誘導体 - Google Patents

多環式グアニン誘導体

Info

Publication number
JPH0747589B2
JPH0747589B2 JP3512084A JP51208491A JPH0747589B2 JP H0747589 B2 JPH0747589 B2 JP H0747589B2 JP 3512084 A JP3512084 A JP 3512084A JP 51208491 A JP51208491 A JP 51208491A JP H0747589 B2 JPH0747589 B2 JP H0747589B2
Authority
JP
Japan
Prior art keywords
phenylmethyl
purin
methyl
alkyl
title compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP3512084A
Other languages
English (en)
Japanese (ja)
Other versions
JPH05508647A (ja
Inventor
ヌースタッド，バーナード・アール
リンド，ネイル・エイ
マクキットリック，ブライアン・エイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schering Plough Corp
Original Assignee
Schering Plough Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Corp filed Critical Schering Plough Corp
Publication of JPH05508647A publication Critical patent/JPH05508647A/ja
Publication of JPH0747589B2 publication Critical patent/JPH0747589B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Filtering Materials (AREA)
JP3512084A 1990-06-21 1991-06-20 多環式グアニン誘導体 Expired - Fee Related JPH0747589B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54156890A 1990-06-21 1990-06-21
US541,568 1990-06-21
PCT/US1991/004154 WO1991019717A1 (en) 1990-06-21 1991-06-20 Polycyclic guanine derivatives

Publications (2)

Publication Number Publication Date
JPH05508647A JPH05508647A (ja) 1993-12-02
JPH0747589B2 true JPH0747589B2 (ja) 1995-05-24

Family

ID=24160139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3512084A Expired - Fee Related JPH0747589B2 (ja) 1990-06-21 1991-06-20 多環式グアニン誘導体

Country Status (21)

Country Link
US (1) US5393755A (enExample)
EP (1) EP0538332B1 (enExample)
JP (1) JPH0747589B2 (enExample)
KR (1) KR960004532B1 (enExample)
AT (1) ATE155786T1 (enExample)
AU (1) AU651607B2 (enExample)
CA (1) CA2085733C (enExample)
CZ (1) CZ281920B6 (enExample)
DE (1) DE69126980T2 (enExample)
FI (1) FI925731A7 (enExample)
HU (1) HUT65623A (enExample)
IE (1) IE912126A1 (enExample)
IL (1) IL98559A0 (enExample)
NO (1) NO924940D0 (enExample)
NZ (1) NZ238609A (enExample)
OA (1) OA09723A (enExample)
PL (1) PL169481B1 (enExample)
RU (1) RU2080322C1 (enExample)
TW (1) TW197441B (enExample)
WO (1) WO1991019717A1 (enExample)
ZA (1) ZA914727B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW270118B (enExample) * 1993-02-26 1996-02-11 Schering Corp
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
ZA969888B (en) * 1995-11-28 1997-05-26 Schering Corp 2'-[[4'-halo-[1,1-biphenyl]-4-yl]methyl]-5'-methyl-spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-ones
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6969719B2 (en) * 2001-08-28 2005-11-29 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
EP1790652A1 (en) * 2001-08-28 2007-05-30 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
US20030211040A1 (en) 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
CN1585771A (zh) * 2001-11-09 2005-02-23 先灵公司 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
AR040232A1 (es) * 2002-05-31 2005-03-23 Schering Corp Proceso para preparar inhibidores de la xantina fosfodiesterasa v, y precursores de los mismos
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
CN1860119A (zh) * 2003-07-31 2006-11-08 先灵公司 用于治疗勃起功能障碍的黄嘌呤磷酸二酯酶5抑制剂代谢物及其衍生物
US7553837B2 (en) * 2003-08-01 2009-06-30 Nippon Soda Co., Ltd. Phenylazole compounds production process and antioxidants
KR20060101762A (ko) * 2003-11-21 2006-09-26 쉐링 코포레이션 포스포디에스테라제 ｖ 억제제 제형
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
CN101248050B (zh) 2005-06-06 2013-07-17 武田药品工业株式会社 有机化合物
US20080194592A1 (en) * 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
CA2631129A1 (en) * 2005-11-09 2007-05-18 Tosoh Corporation Nucleobase having perfluoroalkyl group and process for producing the same
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP2023729B1 (en) 2006-06-06 2016-05-04 Intra-Cellular Therapies, Inc. Organic compounds
JP2010509399A (ja) * 2006-11-13 2010-03-25 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
EP2089034A4 (en) * 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
RU2010101611A (ru) * 2007-06-21 2011-07-27 Шеринг Корпорейшн (US) Полициклические производные гуанина и способы их применения
EP2240490B1 (en) 2007-12-06 2013-09-04 Takeda Pharmaceutical Company Limited Organic compounds
WO2009073210A1 (en) 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Organic compounds
US8859564B2 (en) 2008-12-06 2014-10-14 Intra-Cellular Therapies, Inc. Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1
CA2740391A1 (en) * 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
ES2551133T3 (es) * 2008-12-06 2015-11-16 Intra-Cellular Therapies, Inc. Compuestos de 4,5,7,8-tetrahidro-4-oxo-2H-imidazo[1,2-a]pirrolo[3,4-e]pirimidina como inhibidores de PDE1
MX2011005932A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
EA201170771A1 (ru) 2008-12-06 2012-01-30 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2010065147A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
JP2012518685A (ja) 2009-02-25 2012-08-16 イントラ−セルラー・セラピーズ・インコーポレイテッド 眼障害のためのｐｄｅ１阻害剤
JP5765239B2 (ja) * 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
WO2011081915A2 (en) * 2009-12-15 2011-07-07 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2012171016A1 (en) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Organic compounds
EP2956141A4 (en) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc NEW USES
PL2970279T3 (pl) 2013-03-15 2021-05-31 Intra-Cellular Therapies, Inc. Związki organiczne
EP3479825B1 (en) 2013-03-15 2021-02-17 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns or pns diseases or disorders
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
ES2732442T3 (es) 2014-06-20 2019-11-22 Intra Cellular Therapies Inc Compuestos orgánicos
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
ES2745819T3 (es) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
WO2016044667A1 (en) 2014-09-17 2016-03-24 Intra-Cellular Therapies, Inc. Compounds and methods
WO2016090382A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
RU2709786C2 (ru) 2014-12-06 2019-12-20 Интра-Селлулар Терапиз, Инк. Органические соединения
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
AU2017388054B2 (en) 2016-12-28 2022-03-24 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
US11434247B1 (en) 2017-11-27 2022-09-06 Dart Neuroscience Llc Substituted furanopyrimidine compounds as PDE1 inhibitors
EP3746081A4 (en) 2018-01-31 2021-10-27 Intra-Cellular Therapies, Inc. Novel uses
JP7612672B2 (ja) 2019-09-03 2025-01-14 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規化合物
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53103497A (en) * 1977-02-14 1978-09-08 Bristol Myers Co Heterocyclopyrimidines composition and treating method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1095906A (en) * 1977-02-14 1981-02-17 Davis L. Temple, Jr. Heterocyclopyrimidines, compositions and therapeutic process
US5064947A (en) * 1989-03-29 1991-11-12 Merrell Dow Pharmaceuticals Inc. Selective adenosine reseptor compounds
ZA902282B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor compounds
US5173492A (en) * 1989-09-14 1992-12-22 Kyowa Hakko Kogyo Co., Ltd. s-Triazolo(3,4-I)purine derivatives
JP2988711B2 (ja) * 1989-10-20 1999-12-13 協和醗酵工業株式会社 縮合プリン誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53103497A (en) * 1977-02-14 1978-09-08 Bristol Myers Co Heterocyclopyrimidines composition and treating method

Also Published As

Publication number Publication date
PL297299A1 (enExample) 1992-07-13
CZ281920B6 (cs) 1997-04-16
EP0538332B1 (en) 1997-07-23
PL169481B1 (pl) 1996-07-31
AU8199291A (en) 1992-01-07
NZ238609A (en) 1993-12-23
JPH05508647A (ja) 1993-12-02
NO924940L (no) 1992-12-18
US5393755A (en) 1995-02-28
ATE155786T1 (de) 1997-08-15
FI925731A0 (fi) 1992-12-17
NO924940D0 (no) 1992-12-18
HUT65623A (en) 1994-07-28
ZA914727B (en) 1992-03-25
AU651607B2 (en) 1994-07-28
RU2080322C1 (ru) 1997-05-27
DE69126980T2 (de) 1998-01-08
EP0538332A1 (en) 1993-04-28
TW197441B (enExample) 1993-01-01
CZ374992A3 (en) 1993-10-13
CA2085733C (en) 1996-03-05
OA09723A (en) 1993-08-30
CA2085733A1 (en) 1991-12-22
DE69126980D1 (de) 1997-09-04
IL98559A0 (en) 1992-07-15
HU9204032D0 (en) 1993-03-29
FI925731A7 (fi) 1992-12-17
KR960004532B1 (ko) 1996-04-06
IE912126A1 (en) 1992-01-01
WO1991019717A1 (en) 1991-12-26

Similar Documents

Publication Publication Date Title
JPH0747589B2 (ja) 多環式グアニン誘導体
US5824683A (en) 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
EP4025568B1 (en) Rip1 inhibitory compounds and methods for making and using the same
CN1247583C (zh) 三唑并[4,5－d]嘧啶化合物的新晶形和非晶形
EP1453835B1 (en) Adenosine a 2a receptor antagonists
EP2152712B1 (en) Amino-heterocyclic compounds
EP1740591B1 (en) 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
JP4685243B2 (ja) ピリミド［６，１−ａ］イソキノリン−４−オン誘導体
EP1265900B1 (en) 1,5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-d|pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CN1064361C (zh) 具有终端胺化炔醇侧链的黄嘌呤化合物
HK1002935A1 (en) Pyrrolopyrimidine derivatives with antiproliferative action
HK1002935B (en) Pyrrolopyrimidine derivatives with antiproliferative action
KR20010032979A (ko) Ｐｄｅ ｉｖ 억제 작용을 하는 퓨린 화합물과 그의 합성방법
JP2004517852A (ja) インドール誘導体および５−ｈｔ２ｂおよび５−ｈｔ２ｃ受容体リガンドとしてのそれらの使用
AU5093396A (en) 6-aryl pyrazolo{3,4-d}pyrimidin-4-ones and compositions and methods of use thereof
IE66336B1 (en) Imidazoquinoxaline compounds and their preparation and use
BE1005473A3 (fr) Derives heterocycliques.
JP2008501775A (ja) オキシトシン拮抗剤としての置換トリアゾール誘導体
JP2000501095A (ja) ２’‐［［４’‐ハロ‐［１，１’‐ビフェニル］‐４‐イル］メチル］‐５’‐メチル‐スピロ［シクロペンタン‐１，７’（８’Ｈ）‐［３Ｈ］イミダゾ［２，１‐ｂ］プリン］‐４’（５’Ｈ）‐オン類
JP2008074874A (ja) 新規インダゾール及びインドロン誘導体及び調合剤としてのそれらの使用
JP2008525384A (ja) アリールピペラジン誘導体及びその５−ｈｔ１ａ受容体リガンドとしての使用
EP1842851A2 (en) Novel compounds
HK1064100B (en) Adenosine a 2a receptor antagonists
HK1111411A (en) Novel compounds
MXPA98004198A (en) 2 '[[4'-halo- [1,1'-bifenyl] -4-il] methyl] -5'-methyl-espiro [ciclopentane-1,7' (8'h) - [3h imidazo [2, 1-b] purin] 4 '(5'h) -o

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090524

Year of fee payment: 14

LAPS Cancellation because of no payment of annual fees